Remepy Launches with $ 15 Million in Funding To Bring First Hybrid Drug To Market
Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $ 10M seed investment round, which together with earlier funding totals $ 15M. The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Ventures, joining previous pre-seed lead investor TechAviv as well as Fresh.fund, Samsung Next, StageNext Fund and 97212 Ventures. - - Remepy's new hybrid drugs combine traditional drugs with its “digital molecules.” Digital molec...
Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=321207